Scientific Advisory Board
David Pompliano
Scientific Advisory Board
Pharmaceutical Industry. Entrepreneur.
Entrepreneur-in-Residence at Third Rock. He has over 20 years of experience in the biopharmaceutical industry, most recently as CEO of BioLeap, a discovery stage platform technology company. Before that, he was a senior pharmaceutical executive at GlaxoSmithKline and Merck, where he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and four registered anti-infective (Altabax) and oncology (Tykerb, Votrient, Promacta) drugs.
Pompliano has BSc and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research as a National Institute of Health Postdoctoral Fellow at Harvard University. He also is Principal and Owner of Sanderling Consulting LLC and serves on the Scientific Advisory Boards of several biotechnology companies.
Jordi Vila
Scientific Advisory Board
Infectious Diseases
MD, PhD. Lecturer in Microbiology, Head of the Department of Clinical Microbiology, Hospital Clínic, School of Medicine, University of Barcelona. Research lecturer at Barcelona Center for International Health Research (CRESIB). +25 years of clinical practice and research in anti-infectives.
Scientific Officer of the European Society of Clinical Microbiology and Infectious Diseases (2002-09) and ECCMID Program Director (2010-2014). Member of the Interscience Conference Program Committee on Antimicrobial Agents and Chemotherapy, ICAAC (2007-10).
John Rex
Scientific Advisory Board
Infectious Diseases
VP and Head of Infection, Global Medicines Development, AstraZeneca. 25 years of drug development experience, including 15 years as an academic investigator (National Institutes of Health, Bethesda, Maryland; University of Texas Medical School-Houston).
Since September 2012 Non-Executive Director at F2G Ltd, a UK-based biotechnology company dedicated to the discovery and development of compounds to treat life-threatening systemic fungal infections.
Jose Vicente Castell
Scientific Advisory Board
Infectious Diseases
PhD, MD, Bs Phar; Professor of Clinical Biochemistry and Immunology at the Faculty of Medicine, University of Valencia. He also reads a postgraduate course on Molecular Toxicology. Director of the Research Institute of the University Hospital La Fe.
Invited Professor at the Biochemisches Institut der Universität Freiburg (1987-1988).
International Award of the European Federation of Pharmaceutical Industries (Heidelberg 1990) for the development of cultured human hepatocytes to investigate the hepatotoxic risk of new drugs to man. Field of expertise include human hepatocytes; drug metabolism and hepatotoxicity and drug-induced allergic hepatitis, cell therapy with human hepatocytes and PSC-derived hepatocytes.
He has authored 360 papers, including scientific articles published in relevant international journals, book chapters and several reviews.
Mike Witty
Scientific Advisory Board – Medicinal chemistry / Drug Design
Medicinal Chemistry
Consultant with 35 years’ of experience in drug discovery. Former Vice-President Pfizer Animal Health R&D with experience in a diverse range of therapeutic areas. Now focused on supporting Neglected Tropical Disease R&D.
Consultant for Medicines for Malaria Venture (MMV), University of Cape Town H3D, Global Alliance for Livestock Veterinary Medicines (GALVmed), Wellcome Trust and Bill & Melinda Gates Foundation.
Former Chairman of GALVmed and member of the MMV Expert Scientific Advisory Committee (ESAC), the WHO-TDR Expert Drug Discovery Advisory Committee and the WHO Helminth Drug Initiative.
Rafael Cantón
Infectious Diseases
PhD, Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal (Madrid, Spain), investigator at the Ramón y Cajal Institute of Health Research (IRYCIS) and associated Professor of Clinical Microbiology at Universidad Complutense de Madrid, Spain. Vice-President of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), ad hoc member of the Steering Committee of the European Society for Clinical Microbiology and Infectious Disease (ESCMID) and currently President of the European Committee for Antimicrobial Susceptibility Testing (EUCAST). He is also associated editor of Clinical Microbiology and Infection journal. He has published more than 300 articles in medical journals and 45 book chapters.
